Halozyme Therapeutics (HALO) Interest Coverage Ratio Growth (3y) (2014 - 2026)
Halozyme Therapeutics (HALO) Interest Coverage Ratio Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 40.09% |
| 10 | Halozyme Therapeutics | 9.69 Bn | 9.37 Bn | 297.47 Mn | 41.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.43% |
| Dec 31, 2025 | -12.05% |
| Sep 30, 2025 | -18.50% |
| Jun 30, 2025 | 61.33% |
| Mar 31, 2025 | -10.08% |
| Dec 31, 2024 | 12.01% |
| Sep 30, 2024 | -5.75% |
| Jun 30, 2024 | -21.27% |
| Mar 31, 2024 | -6.36% |
| Dec 31, 2023 | 20.90% |
| Sep 30, 2023 | 34.38% |
| Jun 30, 2023 | 52.67% |
| Mar 31, 2023 | 178.71% |
| Dec 31, 2022 | 57.37% |
| Sep 30, 2022 | 44.85% |
| Jun 30, 2022 | 59.42% |
| Mar 31, 2022 | 259.56% |
| Dec 31, 2021 | 1,033.66% |
| Sep 30, 2021 | 109.92% |
| Jun 30, 2021 | 144.52% |